PLX-4720

Catalog No.S1152

PLX-4720 Chemical Structure

Molecular Weight(MW): 413.83

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

9 Customer Reviews

  • Combinatorial knockdown of NF1 and C-RAF abrogates NF1-mediated resistance to B-RAF inhibition at the level of ERK phosphorylation. A375 cells were infected with NF1 shRNA and treated with either DMSO or PLX4720 for 16 h. Cell lysates were analyzed for the indicated proteins.

    Cancer Discov 2013 3, 350-62. PLX-4720 purchased from Selleck.

    (D)Melanoma cell lines were treated with 0.5 uM Pi-103 and/or 2 uM PLX4720 for 4 h. Samples were analyzed by Western blotting for the indicated proteins. β-Actin served as a loading control. (E) Melanoma cell lines were treated with a dilution series of Pi-103 either alone or in combination with the BRAFV600E inhibitor PLX4720 at a concentration of 3 uM (D10) or 1 uM (453A0) for 3 d. Total cell numbers were determined with a cell titer blue assay. The Y-axis represents the percentage of living cells.

    Genes Dev 2012 26, 1055-69. PLX-4720 purchased from Selleck.

  • RAF inhibitors induce dimer formation between KSR and RAF, and activate KSR by CRAF. (A) GDC0879 but not PLX4720 induces BRAF/CRAF dimers. Cells overexpressing myc-CRAF and BRAF were treated with drug for 1 h and CRAF immunoprecipitates were immunoblotted for BRAF and CRAF (epitope tagged with myc). (B) GDC0879 but not PLX4720 enhances KSR/BRAF complexes. KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and BRAF after treatment with the indicated drug for 1 h and immunoblotted using antibodies to BRAF. (C) Both GDC0879 and PLX4720 induce KSR/CRAF complexes.KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and myc-CRAF after treatment with the indicated drug for 1 h and immunoblotted for CRAF using myc antibodies. (D and E) Requirement of KSR for drug-induced ERK activation. Lysates fromwild-type and KSR deficient fibroblasts, transfected with RASV12, were treated with the indicated doses of either GDC-0879 (D) or PLX4720 (E) for 1 h. Lysates were immunoblotted for phospho-ERK1 and 2, ERK2, and RASV12. (F) KSR and CRAF cooperate to activate MEK. Cells expressing the indicated constructs were treated with a 50 μM PLX4720 for 2 h before cell lysates were prepared and analyzed for pMEK by immunoblotting. CRAF(TM) refers to the T421M gatekeeper mutant that cannot bind to the drug(4). (G) KSR in vitro kinase reactions. Cells were cotransfected with WT or ATP binding deficient KSR and CRAF and immunoprecipitates prepared after cells were treated with an activating dose of PLX (10 μM) for 1 h. KSR immunoprecipitates were prepared, pretreated with 50 uM PLX4720 to inhibit coprecipitating RAF activity, and then tested for kinase activity using purified MEK. MEK phosphorylation was detected using a pMEK specific antibody.

    Proc Natl Acad Sci USA 2011 108, 6067-6072. PLX-4720 purchased from Selleck.

    PTEN predicts for PLX4720-induced apoptosis. A, basal PTEN and phospho-AKT(pAKT; S473, T308) expression in PTENt (WM164, 451Lu, SK-mel-28, WM983A, WM35, WM51) and PTEN (WM239A, WM266-4, WM793, M233, WM9, 1205Lu) melanoma cell lines. B, MTT assay of PTENt (gray)-expressing versus PTEN (black) cell lines. C, PTENt cells are more sensitive than PTEN cells to PLX4720-mediated apoptosis. Cells treated for 48 hours with 3 or 10 μmol/L PLX4720 before being stained for TMRM and Annexin-V. Apoptosis was measured by flow cytometry. Data shows mean SE mean of 3 independent experiments.*, PTENt cohort significantly different from PTEN cohort(P < 0.05).

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • Loss of PTEN is associated with PI3K/AKT signaling following BRAF inhibition. A, PTENt (WM35, WM164, WM983A) and PTEN (M233, WM9,WM793, 1205Lu) cells were treated with PLX4720 (24 hours: 0.03-3 μmol/L) and probed for phospho-PDK1 (pPDK1), total PDK1, phospho-AKT (pAKT), total AKT (tAKT), phospho-S6 (pS6), and total S6. Numbers indicate relative intensity of pPDK1 normalized to PDK1 and pAKT normalized to tAKT. B, PLX4720 increases pAKT following PTEN knockdown. WM35 cells were incubated with nontargeting siRNA (NT) or 2 different PTEN-specific siRNA's (PTEN) before treatment with either vehicle or PLX4720 (3 μmol/L). C, siRNA knockdown of BRAF increases pAKT in melanoma cell lines that are PTEN. WM164 (PTENt) and WM793 (PTEN) cells were incubated with lipofectamine alone (L), nontargeting siRNA (NT), or BRAF-specific siRNA (BRAF). Protein was extracted, resolved, and probed for BRAF, pAKT, total AKT, and GAPDH.

     

     

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN cells. A, left, Western blot of 1205Lu cells treated with PLX4720 (3 μmol/L, 48 hours), the PI3K inhibitor GDC-0941 (3 μmol/L, 48 hours), or both drugs in combination (PtG); right, immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN cells following PLX4720 treatment (3 μmol/L, 48 hours), the PI3K inhibitor LY294002 (10 μmol/L, 48 hours), or both drugs in combination (PLXtLY). B, left, immunofluorescence staining of PTEN 1205Lu following combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48hours) increases nuclear localization of FOXO3a (green). DAPI is shown in blue. Magnification 40. Right, combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48 hours) increases PTEN WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 μmol/L PLX4720, 48 hours) in the PTENt WM35. C, PTEN cells were treated with PLX4720 (3 μmol/L, 48 hours), GDC-0941 (3 μmol/L, 48hours), or a combination of the 2 drugs (3Pt3G) before Annexin-V staining was analyzed by flow cytometry (*, P < 0.05 between the drug combination and each inhibitor alone). D, combined BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN) from therapy. Spheroids of 1205Lu cells were treated with either PLX4720 alone (3 and 10 μmol/L: data shows 3 μmol/L), LY294002 (10 μmol/L) alone or a combination of the 2 drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to recover for 120 hours. Micrograph shows viability staining (green ?live cells, red ?dead cells). Magnification 10.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • LC-MRM identifies differential regulation of BIM in PTENt and PTEN cell lines following PLX4720 treatment. A, representative LC-MRM data showing the fold changes in the expression of Bak, Bax, Bcl-2, Bcl-w, Bcl-xL, BID, BIM, Bok, and Mcl-1 over internal standard in the WM164 (PTENt) and 1205Lu (PTEN) cell lines following treatment with PLX4720 (10 μmol/L, 0-48 hours). Statistical analysis of BIM fold change in PTEN versus PTENt. *, P < 0.05. B, Western blot showing BIM expression following PLX4720 treatment (10 μmol/L, 0-48 hours) in PTEN (WM793, 1205Lu) and WM164 cell lines (PTENt). C, immunofluorescence staining, showing expression of BIM and DAPI staining of PTEN (M233, WM9, WM793, 1205Lu) and PTENt (WM35, WM164, WM983A) cells following PLX4720 treatment (3 μmol/L, 48 hours).D, Western blot showing BAD phosphorylation following treatment with PLX4720 (0-48 hours) in PTEN (WM793,1205Lu) and PTENt WM164. Annexin V binding following treatment with 3 or 10 μmol/L PLX4720 (48 hours) showing increased apoptosis in WM793 stably overexpressing WT BAD. *, P < 0.05.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    B-RafV600E mutated melanoma line, SK-MEL-28, was treated with different doses of PLX-4720 for 4 h or 22 h.  Cell lysates were analyzed by Western blotting to determine the levels of phosphorylated MEK1/2 (pMEK1/2) and phosphorylated ERK1/2 (pERK1/2). MEK1/2 is the substrate of B-Raf while ERK1/2 is the substrate of MEK1/2.  Data show that phosphorylation of MEK1/2 and ERK1/2 was significantly inhibited by PLX-4720 treatment although total MEK1/2 or ERK1/2 protein levels were not affected. No pMEK1/2 or pERK1/2 signal was detected even after prolonged exposure, indicating that the inhibitor at 1 μM is very effective in blocking the constitutive kinase activity of B-RafV600E.  This data is consistent with the previous result demonstrating the effect of PLX-4720 in the B-RafV600E mutated melanoma line, A375 – Fig. 2A, Nature 464:431 (2010)

     

     

    Dr. Jong-In Park of Medical College of Wisconsin. PLX-4720 purchased from Selleck.

  • A dose titration of PLX-4720 in A375 melanoma cells which possess a V600E B-Raf mutation.Effects of  increasing PLX-4720 dose on Erk phosphorylation and on tumor cell proliferation as determined by MTT  assay are shown.

     

     

    Dr. Daniel C.Cho of Harvard Medical School. PLX-4720 purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 M4TMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXBTWM2OD1yLkC3OFU4KM7:TR?= M{\zWnNCVkeHUh?=
EoL-1-cell Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HOS2lEPTB;MD6xOFE3PiEQvF2= MUXTRW5ITVJ?
C32 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPtTWM2OD1yLkG1NVMyKM7:TR?= MVXTRW5ITVJ?
M14 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCwTWM2OD1yLkKxO|U4KM7:TR?= NVTXd|JuW0GQR1XS
CP50-MEL-B NYO1XWh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXn[JdKSzVyPUCuNlk4QDRizszN MXrTRW5ITVJ?
A101D NWDTW5Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnGTWM2OD1yLkOyOVg6KM7:TR?= NWrIVJd2W0GQR1XS
G-361 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7NV4tKSzVyPUCuN|Q3OzdizszN MmHrV2FPT0WU
HT-144 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQZW9KSzVyPUCuN|Y{OjlizszN M3fr[HNCVkeHUh?=
ACN NInrW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwM{i0O|ch|ryP NFrsOW1USU6JRWK=
COLO-829 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwM{i5Olgh|ryP M3raZnNCVkeHUh?=
MEL-HO NXLjfHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfwTWM2OD1yLkSxNVc6KM7:TR?= Mme5V2FPT0WU
SH-4 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m1SGlEPTB;MD60NVQzOiEQvF2= NF\hdZVUSU6JRWK=
SK-MEL-3 NXjONZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNUG1Olgh|ryP Mmi1V2FPT0WU
A375 M1G0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDCZZlKSzVyPUCuOlc{PTlizszN M2Ta[XNCVkeHUh?=
MMAC-SF Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3UR2tKSzVyPUCuOlg3OTRizszN NVLJUoNCW0GQR1XS
BHT-101 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwN{C3NFIh|ryP MXjTRW5ITVJ?
K5 M2nDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnwOmZHUUN3ME2wMlc3OTR6IN88US=> NXva[VNCW0GQR1XS
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvSV2tKSzVyPUCuO|k3PDRizszN M3jBXHNCVkeHUh?=
RVH-421 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XhSmlEPTB;MD64Olc6PiEQvF2= NEHYb41USU6JRWK=
HCC2218 NGrqc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ufm1ZUUN3ME2wMlg4QDR2IN88US=> MYLTRW5ITVJ?
WM-115 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TnfWlEPTB;MD64PFY6OiEQvF2= MYjTRW5ITVJ?
SK-MEL-28 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjZT4RKSzVyPUGuNFQ2PjlizszN MXPTRW5ITVJ?
COLO-679 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LkUmlEPTB;MT6xNFQ3PCEQvF2= NFTi[HRUSU6JRWK=
MZ7-mel MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XDOGlEPTB;MT6xOFk3OyEQvF2= Mk\IV2FPT0WU
SK-MEL-30 NWPtcZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwM{OzPFYh|ryP MnThV2FPT0WU
NCI-H209 M2XKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XmSGlEPTB;MT62NFg3KM7:TR?= NIfJdmxUSU6JRWK=
HTC-C3 NEnHW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTOVWRzUUN3ME2xMlY3Ojl2IN88US=> MXrTRW5ITVJ?
KARPAS-45 NHXhWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjhXGdpUUN3ME2yMlA1QTd6IN88US=> MUTTRW5ITVJ?
NCI-SNU-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HacmlEPTB;Mj6xNVk3QSEQvF2= M2\pOHNCVkeHUh?=
KP-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXTXpTUUN3ME2yMlMxPzh5IN88US=> MVXTRW5ITVJ?
PA-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH0bZFKUUN3ME2yMlczPjd|IN88US=> NVjFRoZXW0GQR1XS
HuO-3N1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnJTWM2OD1{Lki3PVQ3KM7:TR?= MXTTRW5ITVJ?
NCI-H358 M{HpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwOUKyN|Ih|ryP MmO5V2FPT0WU
CTB-1 M1fXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD1|LkSwNVc3KM7:TR?= NVvaZlRLW0GQR1XS
697 M4XW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwNUWyOlYh|ryP M3HDRnNCVkeHUh?=
CP66-MEL M2TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHod41KSzVyPUSuNVU6OjdizszN MYLTRW5ITVJ?
NB13 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfNRnk4UUN3ME20MlQ6OTd7IN88US=> MoX0V2FPT0WU
DBTRG-05MG NWniZXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK3VnNKSzVyPUSuOVM{OjVizszN NH3Je4tUSU6JRWK=
A2058 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O4PWlEPTB;ND63NlE3PCEQvF2= NEHvdFJUSU6JRWK=
KG-1 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMUW1DUUN3ME20Mlc{QTB6IN88US=> NEnYSIJUSU6JRWK=
8305C M1:2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\MTYFLUUN3ME21MlE5PzNizszN MmTPV2FPT0WU
RPMI-7951 NV;uTGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXVTIJxUUN3ME21MlgxOjh|IN88US=> NF7VRpZUSU6JRWK=
CHL-1 NUfqPWYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTVwOUe2NFMh|ryP MWLTRW5ITVJ?
TI-73 M1XUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS3VJVKSzVyPU[uNFA6ODJizszN MkPEV2FPT0WU
HT-1080 NYLm[4x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTwZlBoUUN3ME22MlExQTR4IN88US=> NULFPWJxW0GQR1XS
ES5 NHSxR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3aTWM2OD14LkG0PVI1KM7:TR?= NHTkXYRUSU6JRWK=
8-MG-BA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP5cFdKSzVyPU[uNVgyOjlizszN MV3TRW5ITVJ?
NB7 NUjqVms4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTZwMkGzO|Mh|ryP NEjDU5BUSU6JRWK=
H4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf3TWM2OD14LkKyOFk{KM7:TR?= Mnn5V2FPT0WU
CAL-72 M2OwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZwNEW0NlMh|ryP M{ixd3NCVkeHUh?=
HCC1806 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\LTWM2OD14LkixPVMyKM7:TR?= MlWxV2FPT0WU
BCPAP MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1eycmlEPTB;Nz6yNVc3PCEQvF2= NEDkfYJUSU6JRWK=
LB2241-RCC M3[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XqWGlEPTB;Nz6zOlkxPyEQvF2= MYjTRW5ITVJ?
COLO-741 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH2[2FKSzVyPUiuNFE3PzlizszN M{L3[nNCVkeHUh?=
HSC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwMEewOlgh|ryP NVjpVWh7W0GQR1XS
SW982 M4jUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LNY5KSzVyPUiuOFE2OTZizszN M1j5V3NCVkeHUh?=
GCT MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHW[FRKSzVyPUiuO|U{OTRizszN M2HDenNCVkeHUh?=
KY821 M3X4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorCTWM2OD17LkC1NVc5KM7:TR?= NITqeJhUSU6JRWK=
JVM-3 NHHZb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLNTWM2OD17LkW2PVk6KM7:TR?= M{LsfHNCVkeHUh?=
RS4-11 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T0cmlEPTB;OT62NFQ5KM7:TR?= NUfBW|JLW0GQR1XS
VA-ES-BJ NGrZZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPpN4VKSzVyPUGwMlAyPDlizszN M3HwdHNCVkeHUh?=
A431 NWHjUZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLEeWlKSzVyPUGwMlQzOTJizszN MontV2FPT0WU
LXF-289 NHLRfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PnTmlEPTB;MUCuOFU5KM7:TR?= NFTSdG5USU6JRWK=
SK-MEL-24 M1rTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7y[29KSzVyPUGwMlgzPzRizszN NGDGb45USU6JRWK=
NOS-1 NH\UNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2UG9KSzVyPUGwMlg1PzJizszN MYnTRW5ITVJ?
KNS-62 NGHqRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:2PHMyUUN3ME2xNU4zPDB2IN88US=> MU\TRW5ITVJ?
SK-HEP-1 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTZco5VUUN3ME2xNU4{PTJ5IN88US=> MnHQV2FPT0WU
A3-KAW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fSPGlEPTB;MUGuO|E4QCEQvF2= NIq5XIxUSU6JRWK=
SK-LU-1 NVP5NFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDPTWM2OD1zMj6yOlU2KM7:TR?= M{ezUHNCVkeHUh?=
TYK-nu NYTocpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHQWYRKSzVyPUGyMlM6OzJizszN MXHTRW5ITVJ?
NMC-G1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nBfmlEPTB;MUKuOlA3OiEQvF2= NWDEbGtRW0GQR1XS
BB65-RCC NEHuNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXRd2Q2UUN3ME2xNk44OTZ7IN88US=> NF62flJUSU6JRWK=
QIMR-WIL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{Lki4N|Mh|ryP MVXTRW5ITVJ?
D-566MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[zTWM2OD1zMz65OVc3KM7:TR?= NHr4bohUSU6JRWK=
KYSE-140 M1;Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF2LkC3OVMh|ryP MmXRV2FPT0WU
SCC-4 NEW2S2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5S3hKUUN3ME2xOE4{OzV7IN88US=> M13kenNCVkeHUh?=
U251 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnHdHdTUUN3ME2xOE45PDl{IN88US=> NXTQSWREW0GQR1XS
D-542MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLxNWFKSzVyPUG0MlkzOjJizszN MX7TRW5ITVJ?
LAMA-84 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF2Lkm5N|Ih|ryP MUPTRW5ITVJ?
NCI-H720 NYr6RZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF3LkK2PFQh|ryP NXfnd443W0GQR1XS
DEL NYXyPWFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5SmlEPTB;MUWuOFI6OyEQvF2= MmrKV2FPT0WU
SBC-1 NX21Tll{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPyZoRKSzVyPUG1MlQ{ODVizszN NUjPTnJlW0GQR1XS
ECC10 NUTlZoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPVNHpoUUN3ME2xOU41PDV6IN88US=> M1zEZXNCVkeHUh?=
Daoy MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXDTWM2OD1zNT63OlE3KM7:TR?= NYKy[3ROW0GQR1XS
SCH MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1zNT63PFM2KM7:TR?= NXvldHZnW0GQR1XS
MZ2-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rIOmlEPTB;MU[uNFY1PiEQvF2= M3jlUXNCVkeHUh?=
CAL-12T MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL5TWM2OD1zNj60PFYzKM7:TR?= M3jNWXNCVkeHUh?=
KE-37 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj6TWM2OD1zNj64NVA4KM7:TR?= M2XWdHNCVkeHUh?=
LS-411N NF34bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj4ZnVKSzVyPUG3MlEyQCEQvF2= NX7CTJBTW0GQR1XS
NCI-H2228 NXW2dZRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7sXmhKSzVyPUG3MlMxPzFizszN MW\TRW5ITVJ?
SK-MEL-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvBc41qUUN3ME2xO{41QTZ3IN88US=> NEPUbYJUSU6JRWK=
HN M2HVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn0WIlKSzVyPUG3MlczPDhizszN NGLVbWhUSU6JRWK=
NCI-H1648 NXHX[WlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\4TWM2OD1zNz64NVgh|ryP NVXLd2VuW0GQR1XS
IA-LM MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyzfIdKUUN3ME2xPE4{OTd{IN88US=> M{nue3NCVkeHUh?=
EW-13 NYfzVGgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrHOJBZUUN3ME2xPE42PzB6IN88US=> NGrWS|JUSU6JRWK=
YKG-1 M2jaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqzZXpKSzVyPUG5MlU4OTFizszN NYDqSGNNW0GQR1XS
KNS-81-FD NWnYU|dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;0THViUUN3ME2xPU42QDV6IN88US=> Mn\1V2FPT0WU
23132-87 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X2[GlEPTB;MUmuO|Y1OiEQvF2= Mo[yV2FPT0WU
NUGC-3 M2PSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF7Lkm4PFch|ryP M4nCfnNCVkeHUh?=
5637 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDVeGtkUUN3ME2yNE4xPDd6IN88US=> MWXTRW5ITVJ?
NCI-H1755 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nhcmlEPTB;MkCuOFc3PCEQvF2= NYrjV5NLW0GQR1XS
RH-18 M3TlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[zNGhUUUN3ME2yNE42PzR6IN88US=> NV7FT3ZlW0GQR1XS
RXF393 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXh[4xKSzVyPUKwMlY4PTZizszN NX35VHl2W0GQR1XS
LU-134-A MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJyLkewOVYh|ryP NGnEVllUSU6JRWK=
TE-12 M2O2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\odYJzUUN3ME2yNE44OjBzIN88US=> MV;TRW5ITVJ?
MOLT-4 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:1SGlEPTB;MkGuNVkyPSEQvF2= MkfJV2FPT0WU
IGR-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJzLkO3PVYh|ryP NHTaeFBUSU6JRWK=
HOP-92 M{e4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DPb2lEPTB;MkGuOFk5PyEQvF2= MUPTRW5ITVJ?
SK-MES-1 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL1Oo5[UUN3ME2yNU44OzhzIN88US=> M2nCN3NCVkeHUh?=
LU-65 M{HlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLtTWM2OD1{MT64OlI1KM7:TR?= MkHrV2FPT0WU
MS-1 NXu4b2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i4bWlEPTB;MkKuNVIxOyEQvF2= NGfjOlFUSU6JRWK=
LoVo MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLxVVBKSzVyPUKyMlI1PCEQvF2= Mlq5V2FPT0WU
A704 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rKTWlEPTB;MkKuOVE2PSEQvF2= MYPTRW5ITVJ?
HT-1376 NFfKN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme0TWM2OD1{Mj62NFU6KM7:TR?= Mn;0V2FPT0WU
IST-MEL1 NHX3cmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\kTmlEPTB;MkKuOlc2OSEQvF2= NXrUWWY6W0GQR1XS
Ramos-2G6-4C10 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ{LkezOlYh|ryP NGHSb29USU6JRWK=
T47D NXXxUHVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1{Mj63PVc6KM7:TR?= MWDTRW5ITVJ?
HT-1197 NUiz[lVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy1OmlKSzVyPUKzMlA5OTdizszN NXOyVpJYW0GQR1XS
LB2518-MEL M3zOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ScZlKSzVyPUKzMlY1OTJizszN M1XPd3NCVkeHUh?=
J-RT3-T3-5 NGrRfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGxTWM2OD1{ND63OVk2KM7:TR?= Mk\TV2FPT0WU
SK-NEP-1 M4TxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\iRWpKSzVyPUK0Mlg4PDRizszN M3nxWHNCVkeHUh?=
NCI-H526 NHX3eXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT4SJlFUUN3ME2yOU4xODJ|IN88US=> MkLMV2FPT0WU
IST-SL1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ3LkK3OVEh|ryP MXnTRW5ITVJ?
HH MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnr[G9YUUN3ME2yOU4{OTl{IN88US=> MVLTRW5ITVJ?
NCI-H82 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\nTWM2OD1{NT65N|gh|ryP MknlV2FPT0WU
SNU-449 NGLUN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITVS3dKSzVyPUK3MlIxOThizszN NYHoOmVvW0GQR1XS
COR-L23 NETvNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf2WY5wUUN3ME2yO{4zQDF|IN88US=> MYHTRW5ITVJ?
LOXIMVI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ftUWlEPTB;MkeuN|Y5KM7:TR?= M1TsUHNCVkeHUh?=
GR-ST NFvvbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXBTWM2OD1{Nz62O|A3KM7:TR?= NEHPZVZUSU6JRWK=
NCI-SNU-1 M3LpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q0ZWlEPTB;MkeuPVQ1KM7:TR?= M2TpW3NCVkeHUh?=
ALL-PO NFLnd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXixcHRvUUN3ME2yPE4yPjB2IN88US=> NFH3d2tUSU6JRWK=
ML-2 NWHrOopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv3TWM2OD1{OD6yPFE1KM7:TR?= Mmr4V2FPT0WU
HOP-62 M2f1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETXRlVKSzVyPUK4MlcyOyEQvF2= NIntN|NUSU6JRWK=
EGI-1 NETOUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC2TWM2OD1{OD64PFQ2KM7:TR?= M1jmfnNCVkeHUh?=
TCCSUP Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHDdVg2UUN3ME2yPE46Ojd{IN88US=> M{DQOXNCVkeHUh?=
LB996-RCC NVXGSZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CyXGlEPTB;MkmuOVY5OiEQvF2= NXjUboh1W0GQR1XS
LCLC-97TM1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrv[oxsUUN3ME2zNk4yQTZ2IN88US=> M{TvcnNCVkeHUh?=
NCI-H1304 M4nVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2SmlEPTB;M{KuN|MxOSEQvF2= MVnTRW5ITVJ?
KP-N-YS M2PWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PmdGlEPTB;M{KuOVk4OyEQvF2= MYHTRW5ITVJ?
NCI-H1770 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fHRWlEPTB;M{OuNVY1QCEQvF2= MlnxV2FPT0WU
EM-2 NYe0bIE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fVPGlEPTB;M{OuOlUxPCEQvF2= M2\BVHNCVkeHUh?=
ChaGo-K-1 M17GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrCTWM2OD1|Mz63NlM3KM7:TR?= NGX2PIVUSU6JRWK=
ACHN M{LHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn4dVdKSzVyPUOzMlg{QDVizszN NYDYPXREW0GQR1XS
MN-60 NY\RZ3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0dGlEPTB;M{OuPFU1PCEQvF2= MoHNV2FPT0WU
EW-18 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHlPJlKSzVyPUOzMlg6PzFizszN M{DXb3NCVkeHUh?=
KGN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zlTmlEPTB;M{WuO|I6OiEQvF2= MljsV2FPT0WU
U031 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WwUWlEPTB;M{WuPFE{OiEQvF2= NGG0eXFUSU6JRWK=
HMV-II MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN4LkC3O|Qh|ryP MorHV2FPT0WU
L-363 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN5Lk[0OVUh|ryP NEnGeo5USU6JRWK=
NCI-H1155 NGKyOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN6LkCwNVUh|ryP M37xZXNCVkeHUh?=
NCI-H1793 NXfUUW54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j2dWlEPTB;M{iuNVAzPiEQvF2= NHTudmlUSU6JRWK=
P30-OHK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf4N3pKUUN3ME2zPE4yOzN{IN88US=> Mn\XV2FPT0WU
AN3-CA NFjqNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITzT4JKSzVyPUO4MlE3OTVizszN Mo\wV2FPT0WU
UACC-257 M1nZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXubGdKSzVyPUO4Mlc6KM7:TR?= NIrPR3dUSU6JRWK=
MCF7 NIf3dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jYVWlEPTB;M{muPFYzQSEQvF2= MmHIV2FPT0WU
KP-N-YN M{X5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPvTWM2OD12MD60Nlg2KM7:TR?= NGnmc3ZUSU6JRWK=
T98G MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWruWWk5UUN3ME20NE41QTV5IN88US=> NWDufo05W0GQR1XS
HGC-27 NWPOW3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTR|LkK3OEDPxE1? MXnTRW5ITVJ?
NCI-H1092 M{e0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGdmlEPTB;NEOuNlg6PSEQvF2= M1[1d3NCVkeHUh?=
KARPAS-299 NHr2cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjTVWJCUUN3ME20N{4{ODdzIN88US=> MmjSV2FPT0WU
LB1047-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xx[GlEPTB;NESuPVk2QSEQvF2= NXjkdnRCW0GQR1XS
786-0 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nyZWlEPTB;NEWuOlUh|ryP NHrYRXlUSU6JRWK=
HCC2157 NFvKSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiwTWM2OD12Nj6wN|U6KM7:TR?= NFHFbVVUSU6JRWK=
NY M1HwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR4LkG3O|gh|ryP M3;EUnNCVkeHUh?=
EFM-19 NIf5bpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6wTWM2OD12Nj63OVM{KM7:TR?= NYnnN5pPW0GQR1XS
EW-16 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTR4Lke4NFYh|ryP MYrTRW5ITVJ?
UM-UC-3 M1ztcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMTWM2OD12Nj64NFU6KM7:TR?= NXq0TJJDW0GQR1XS
HT-29 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nNfWlEPTB;NEeuPFc6OiEQvF2= MU\TRW5ITVJ?
LN-405 NF;HZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR6LkC4Nlch|ryP M2jtWHNCVkeHUh?=
NCI-H727 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfh[lZKSzVyPUS4Mlc4OjZizszN NGDEWFdUSU6JRWK=
D-502MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn31TWM2OD12OD65Olc3KM7:TR?= NWL5dmlQW0GQR1XS
GMS-10 NXfwTodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO1TWM2OD12OT6yPVc1KM7:TR?= MlfaV2FPT0WU
MEL-JUSO NF7Fe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvrTVlKSzVyPUS5MlM1PyEQvF2= MUHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
+ Expand
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Formulation: Suspended in vehicle (5% DMSO, 1% methylcellulose)
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy PLX-4720 | PLX-4720 supplier | purchase PLX-4720 | PLX-4720 cost | PLX-4720 manufacturer | order PLX-4720 | PLX-4720 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID